Literature DB >> 29763303

Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Arun K Ghosh1, Prasanth R Nyalapatla1, Satish Kovela1, Kalapala Venkateswara Rao1, Margherita Brindisi1, Heather L Osswald1, Masayuki Amano2,3, Manabu Aoki2,3,4, Johnson Agniswamy5, Yuan-Fang Wang5, Irene T Weber5, Hiroaki Mitsuya2,6,4.   

Abstract

The design, synthesis, and biological evaluation of a new class of HIV-1 protease inhibitors containing stereochemically defined fused tricyclic polyethers as the P2 ligands and a variety of sulfonamide derivatives as the P2' ligands are described. A number of ring sizes and various substituent effects were investigated to enhance the ligand-backbone interactions in the protease active site. Inhibitors 5c and 5d containing this unprecedented fused 6-5-5 ring system as the P2 ligand, an aminobenzothiazole as the P2' ligand, and a difluorophenylmethyl as the P1 ligand exhibited exceptional enzyme inhibitory potency and maintained excellent antiviral activity against a panel of highly multidrug-resistant HIV-1 variants. The umbrella-like P2 ligand for these inhibitors has been synthesized efficiently in an optically active form using a Pauson-Khand cyclization reaction as the key step. The racemic alcohols were resolved efficiently using a lipase catalyzed enzymatic resolution. Two high resolution X-ray structures of inhibitor-bound HIV-1 protease revealed extensive interactions with the backbone atoms of HIV-1 protease and provided molecular insight into the binding properties of these new inhibitors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29763303      PMCID: PMC6044451          DOI: 10.1021/acs.jmedchem.8b00298

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  52 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

3.  Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.

Authors:  Jianwei Yan; Ning Huang; Shukun Li; Liu-Meng Yang; Weiqiang Xing; Yong-Tang Zheng; Youhong Hu
Journal:  Bioorg Med Chem Lett       Date:  2012-01-21       Impact factor: 2.823

4.  Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.

Authors:  Christopher J Bungard; Peter D Williams; Jeanine E Ballard; David J Bennett; Christian Beaulieu; Carolyn Bahnck-Teets; Steve S Carroll; Ronald K Chang; David C Dubost; John F Fay; Tracy L Diamond; Thomas J Greshock; Li Hao; M Katharine Holloway; Peter J Felock; Jennifer J Gesell; Hua-Poo Su; Jesse J Manikowski; Daniel J McKay; Mike Miller; Xu Min; Carmela Molinaro; Oscar M Moradei; Philippe G Nantermet; Christian Nadeau; Rosa I Sanchez; Tummanapalli Satyanarayana; William D Shipe; Sanjay K Singh; Vouy Linh Truong; Sivalenka Vijayasaradhi; Catherine M Wiscount; Joseph P Vacca; Sheldon N Crane; John A McCauley
Journal:  ACS Med Chem Lett       Date:  2016-05-09       Impact factor: 4.345

5.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

6.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  HIV-1 Protease: Structural Perspectives on Drug Resistance.

Authors:  Irene T Weber; Johnson Agniswamy
Journal:  Viruses       Date:  2009-12-03       Impact factor: 5.048

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  8 in total

1.  Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.

Authors:  Mei Zhu; Yue Dou; Ling Ma; Biao Dong; Fan Zhang; Guoning Zhang; Juxian Wang; Jinming Zhou; Shan Cen; Yucheng Wang
Journal:  ACS Med Chem Lett       Date:  2020-03-31       Impact factor: 4.345

2.  Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

Authors:  Gordon J Lockbaum; Florian Leidner; Linah N Rusere; Mina Henes; Klajdi Kosovrasti; Gily S Nachum; Ellen A Nalivaika; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Infect Dis       Date:  2018-12-31       Impact factor: 5.084

3.  Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands.

Authors:  Arun K Ghosh; Satish Kovela; Ashish Sharma; Dana Shahabi; Ajay K Ghosh; Denver R Hopkins; Monika Yadav; Megan E Johnson; Johnson Agniswamy; Yuan-Fang Wang; Shin-Ichiro Hattori; Nobuyo Higashi-Kuwata; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2022-03-04       Impact factor: 3.540

4.  Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.

Authors:  Linah N Rusere; Gordon J Lockbaum; Mina Henes; Sook-Kyung Lee; Ean Spielvogel; Desaboini Nageswara Rao; Klajdi Kosovrasti; Ellen A Nalivaika; Ronald Swanstrom; Nese Kurt Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2020-08-03       Impact factor: 7.446

5.  HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.

Authors:  Linah N Rusere; Gordon J Lockbaum; Sook-Kyung Lee; Mina Henes; Klajdi Kosovrasti; Ean Spielvogel; Ellen A Nalivaika; Ronald Swanstrom; Nese Kurt Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2019-08-21       Impact factor: 7.446

Review 6.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

7.  Highly Diastereoselective Intramolecular Asymmetric Oxidopyrylium-olefin [5 + 2] Cycloaddition and Synthesis of 8-Oxabicyclo[3.2.1]oct-3-enone Containing Ring Systems.

Authors:  Arun K Ghosh; Monika Yadav
Journal:  J Org Chem       Date:  2021-05-20       Impact factor: 4.198

Review 8.  Benzothiazoles as potential antiviral agents.

Authors:  Yahya I Asiri; Abdulrhman Alsayari; Abdullatif B Muhsinah; Yahia N Mabkhot; Mohd Z Hassan
Journal:  J Pharm Pharmacol       Date:  2020-07-24       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.